Conversely, no targeted therapy treatments have been approved for cancers with Class 2 and 3 non-V600 BRAF mutations or BRAF fusions—which comprise approximately 35% of all oncogenic BRAF alterations in adult solid tumors [1]. This evidence concerns the gene BRAF and cancer.